HomePharmacologyAntiplatelet

Antiplatelet

View Category

Acute coronary syndromes

ACC 2018 | SMART-DATE: 6 Month DAPT Results Suboptimal in ACS

This study compared 6 vs 12 or more months of dual antiplatelet therapy (DAPT) in patients undergoing acute...
solaci -
Learn More
Antiplatelet

ACC 2018 | TREAT: Ticagrelor + Fibrinolytics’ Effect on Bleeding

Ticagrelor seems as safe as clopidogrel in patients undergoing ST elevation MI treated with fibrinolytics, at least in terms...
solaci -
Learn More
Antiplatelet

Dual Antiplatelet Therapy: Less Is More for Elderly Patients

A recent meta-analysis that will be published soon in JACC Intv offers evidence of benefit derived from...
solaci -
Learn More
Antiplatelet

Transulnar Access: Another Ace Up Our Sleeve Before Transfemoral Access

Transulnar access can be as safe and effective as transradial access, and it is a particularly good...
solaci -
Learn More
Antiplatelet

New Study Shows Ticagrelor + Aspirin Reduce Events Rate

Just when we were starting to understand how long dual antiplatelet therapy should be for our patients, JACC publishes...
solaci -
Learn More
Antiplatelet

What Is the Best Antiplatelet Therapy in Primary Angioplasty at 12 Months?

Both prasugrel and ticagrelor showed superiority in terms of efficacy, reducing the number of major cardiovascular events...
solaci -
Learn More
Antiplatelet

Clinical and Economic Costs Compete in the De-Escalation of Antiplatelet Therapy

Patients undergoing primary angioplasty for ST-segment elevation acute myocardial infarction have similar clinical outcomes at 1 year regardless...
solaci -
Learn More
Antiplatelet

Aspirin During Noncardiac Surgery: Only in Patients with Prior Angioplasty

A new analysis from the POISE-2 study suggests that aspirin should not be withheld prior to noncardiac...
solaci -
Learn More